This report values the global synthetic DNA market at approximately US$5.5B in 2025 and forecasts growth to approximately US$13.0B by 2030, an estimated 18.8% CAGR (2026-2030). North America is the largest regional market at approximately 42% share of 2025 demand, anchored by a dense concentration of biopharmaceutical, academic and contract-research institutions, while Asia Pacific is the fastest-growing region at approximately 25.4% CAGR, led by China's expanding domestic gene-synthesis manufacturing capacity and India's rapid biotechnology-outsourcing growth of approximately 30% CAGR - the fastest of any major market covered in this report.
The global synthetic DNA market grew from an estimated US$3.1B in 2021 to US$5.5B in 2025, a historical CAGR of approximately 15%, as gene editing, cell and gene therapy, and synthetic biology research drove sustained demand for custom oligonucleotides and synthetic genes. By synthesis type, oligonucleotide synthesis leads at 40% share, while gene synthesis is the fastest-growing category at approximately 22% CAGR. By technology, chemical (phosphoramidite) synthesis remains both the largest platform at 55% share and enzymatic DNA synthesis is the fastest-growing at approximately 28% CAGR, reflecting growing interest in longer, higher-fidelity constructs. By application, research and synthetic biology leads global demand at 34% share, while therapeutics and gene/cell therapy is the fastest-growing application at approximately 24% CAGR.
Growth is underpinned by the expansion of CRISPR-based gene editing, rising investment in gene and cell therapy pipelines, growing adoption of synthetic biology across industrial and agricultural biotechnology, and continued build-out of high-throughput, automated synthesis capacity. Key trends reshaping the industry include the commercialization of enzymatic DNA synthesis, growing use of AI-assisted sequence design, expansion of high-throughput array-based synthesis platforms, and rising direct-to-researcher digital ordering. The market's principal challenges include high equipment and reagent costs, biosafety and gene-synthesis-screening compliance requirements, the technical complexity of scaling long and high-fidelity constructs, and continued reliance on skilled molecular-biology personnel.
The competitive landscape spans diversified life-sciences-tools leaders such as Thermo Fisher Scientific, Agilent Technologies and Integrated DNA Technologies (a Danaher company), dedicated gene-synthesis specialists such as Twist Bioscience and GenScript Biotech, and emerging enzymatic-synthesis and CRISPR-focused innovators such as Ansa Biotechnologies and Synthego, with competitive intensity centered on synthesis fidelity, throughput, turnaround time and platform automation. Looking ahead, the global synthetic DNA market enters 2026 as a structurally growing category: expanding gene-therapy pipelines, synthetic-biology commercialization and continued technology innovation in enzymatic and high-throughput synthesis are together expected to sustain demand through 2030.
The global synthetic DNA market grew from an estimated US$3.1B in 2021 to US$5.5B in 2025, a historical CAGR of approximately 15%, as gene editing, cell and gene therapy, and synthetic biology research drove sustained demand for custom oligonucleotides and synthetic genes. By synthesis type, oligonucleotide synthesis leads at 40% share, while gene synthesis is the fastest-growing category at approximately 22% CAGR. By technology, chemical (phosphoramidite) synthesis remains both the largest platform at 55% share and enzymatic DNA synthesis is the fastest-growing at approximately 28% CAGR, reflecting growing interest in longer, higher-fidelity constructs. By application, research and synthetic biology leads global demand at 34% share, while therapeutics and gene/cell therapy is the fastest-growing application at approximately 24% CAGR.
Growth is underpinned by the expansion of CRISPR-based gene editing, rising investment in gene and cell therapy pipelines, growing adoption of synthetic biology across industrial and agricultural biotechnology, and continued build-out of high-throughput, automated synthesis capacity. Key trends reshaping the industry include the commercialization of enzymatic DNA synthesis, growing use of AI-assisted sequence design, expansion of high-throughput array-based synthesis platforms, and rising direct-to-researcher digital ordering. The market's principal challenges include high equipment and reagent costs, biosafety and gene-synthesis-screening compliance requirements, the technical complexity of scaling long and high-fidelity constructs, and continued reliance on skilled molecular-biology personnel.
The competitive landscape spans diversified life-sciences-tools leaders such as Thermo Fisher Scientific, Agilent Technologies and Integrated DNA Technologies (a Danaher company), dedicated gene-synthesis specialists such as Twist Bioscience and GenScript Biotech, and emerging enzymatic-synthesis and CRISPR-focused innovators such as Ansa Biotechnologies and Synthego, with competitive intensity centered on synthesis fidelity, throughput, turnaround time and platform automation. Looking ahead, the global synthetic DNA market enters 2026 as a structurally growing category: expanding gene-therapy pipelines, synthetic-biology commercialization and continued technology innovation in enzymatic and high-throughput synthesis are together expected to sustain demand through 2030.
Table of Contents
1. Introduction
2. Market Size and Growth
3. Market Segmentation
4. Regional and Country Analysis
5. Technology, Application and Evidence Insights
6. Competitive Landscape
7. Company Profiles
8. Strategic Insights and Outlook
List of Tables and Figures
Companies Mentioned
- Twist Bioscience
- Integrated DNA Technologies (IDT)
- GenScript Biotech
- Thermo Fisher Scientific
- Agilent Technologies
- Eurofins Genomics
- Synthego
- Ansa Biotechnologies
